Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Multicenter, Open-Label, Safety, and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)

Trial Profile

A Phase 1b/2, Multicenter, Open-Label, Safety, and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2018

At a glance

  • Drugs SYNT 001 (Primary)
  • Indications Pemphigus vulgaris
  • Focus Adverse reactions; Proof of concept
  • Sponsors Syntimmune
  • Most Recent Events

    • 21 Aug 2018 Phase has changed from phase 1 to phase 1/2 and a 3 cohort has been added.
    • 17 May 2018 Preliminary data from this trial was presented at the International Investigative Dermatology conference, According to a Syntimmune media release.
    • 17 May 2018 Results from Cohort 1 (n=7) presented in the Syntimmune media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top